pharma · Hepatocellular Carcinoma · Liver Cancer
Chinese PLA General
Chinese PLA General Hospital
Chinese PLA General is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Liver Cancer, Gastric Cancer, Colorectal Cancer. NovaPharmaNews links 4 clinical program
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 4
- Drugs
- 9
- Patents
- 0
raltitrexed combined with apatinib
Phase 2 · small molecule · Colorectal Cancer
raltitrexed combined with apatinib for Colorectal Cancer is a Phase 2 program (small_molecule) at Chinese PLA General Hospital with 1 ClinicalTrials.gov record(s).
Internal code AHEAD-311
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Chinese PLA General Hospital
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Colorectal Cancer
- Status
- active
- Trials
- 1